Trials / Terminated
TerminatedNCT03549000
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Triple Negative Breast Cancer (TNBC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Colorectal Cancer Microsatellite Stable (MSS)
- Ovarian Cancer
- Renal Cell Carcinoma (RCC)
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | NZV930 | NZV930, Specified dose on specified days, intravenous (IV) |
| OTHER | PDR001 | PDR001, Specified dose on specified days, intravenous (IV) |
| DRUG | NIR178 | NIR178 Specified dose on specified days, Orally |
Timeline
- Start date
- 2018-07-18
- Primary completion
- 2022-10-17
- Completion
- 2022-10-17
- First posted
- 2018-06-07
- Last updated
- 2024-12-13
Locations
10 sites across 7 countries: United States, Australia, Canada, Japan, Singapore, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03549000. Inclusion in this directory is not an endorsement.